CA
NZ
UK
AU
IND
US
AEON Biopharma (NASDAQ: AEON) has enhanced its capital position by issuing 4,696,102 shares of its Class A common stock, each carrying a nominal par value of $0.0001. The underwriting arrangement generated gross proceeds of roughly $1.5 million, and after expenses the company expects net …
AtriCure (NASDAQ: ATRC) posted earnings of $0.18 per share for the quarter ended June 30, exceeding internal guidance. Revenue reached $153.6 million, reflecting a 12.8% rise compared with the same period last year, and net income climbed to $9.0 million. These results highlight a …
A single trading session captured an unusually wide range of catalysts across eight biopharmaceutical stocks, from a blowout earnings beat to a severe dilution-driven collapse to clinical, regulatory, and partnership news spanning oncology, rare disease, and Alzheimer's research. The moves illustrate just how varied …
MindWalk Holdings (NASDAQ: HYFT) reported a quarterly loss of $0.06 per share, missing the $0.05 consensus estimate by 20%, and shares closed down 18% at $1.18 following the release. The scale of the miss, combined with a sharp year-over-year revenue decline, points to a …
Jaguar Health (NASDAQ: JAGX) disclosed that its subsidiary, Napo Pharmaceuticals, has supplied a proprietary oral solution formulation of crofelemer for compassionate use, even as shares closed down 23% at $1.03. The disconnect between a positive humanitarian development and a sharply negative share price reaction …
HCW Biologics Inc. (NASDAQ: HCWB) requested a Type B pre-IND consultation with the FDA to coordinate on the clinical framework and regulatory roadmap for HCW11-018b, even as shares closed down 14% at $2.88. A pre-IND meeting represents an early but important step in aligning …
Niki BioSolutions, Inc. (NASDAQ: NIKI) revealed that DiamiR Biosciences, its subsidiary, has contracted with Progressive Medical Research (PMR) to deliver Apolipoprotein E (APOE) genotyping services, even as shares closed down 5% at $8.58. APOE genotyping is a well-established area of genetic testing given the …
Novocure (NASDAQ: NVCR) shares closed up 28% at $19.99 after the company reported second-quarter 2026 earnings with net revenue of $183.58 million, up 16% year-over-year and comfortably ahead of the $172.44 million consensus estimate. The scale of the beat, combined with a raised full-year …
China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) announced a $9 million registered direct offering, and shares closed down 84% at $0.33, marking one of the steepest single-day declines recorded across the biopharma sector this year. A decline of this magnitude points to severe dilution concerns …
Neuphoria Therapeutics Inc. (NASDAQ: NEUP) and Scancell Holdings plc (AIM: SCLP) finalized an agreement for an all-stock merger, and Neuphoria shares closed up 18% at $3.92 on the news. The deal represents a cross-border combination bringing together a Nasdaq-listed and an AIM-listed biopharmaceutical company …
Please wait processing your request...